611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
EHR-Based Prompt Ups Hepatitis C Screening for Baby BoomersTravelers to Europe Need Measles Protection: CDCLaser Therapy Shows Promise Against Eye 'Floaters'Health Tip: Ease the Pain of a BlisterChronic Disease Risk Rises With Even Slow, Steady Weight GainAs Your Weight Creeps Up, So Does Your Risk of Heart FailureResearchers Grow Functioning Liver Tissue in MiceMore Than 100 Million Americans Have Diabetes or Prediabetes: CDCMeasles Outbreak Identified in Minnesota Is OngoingMore Evidence That Midlife Weight Gain Harms Your HealthReducing Repeat Hospitalizations Doesn't Harm Patients: StudyImpaired Eyesight May Be First Sign of Zika Damage in BabiesSome Medicines Boost Sensitivity to Sun9/11 Survivors More Likely to Have Heart, Lung DiseasesCould Artificial Sweeteners Raise Your Odds for Obesity?Many Americans Unaware of This Year's Heavy Tick Season: PollAfter Sunburn, High-Dose Vitamin D Cuts Inflammatory MediatorsHealth Tip: At Risk of Heat Illness?Working Too Much Might Tip Heart Into Irregular RhythmQuitting Smoking Can Bring Healthier Sinuses Years Later: StudyThyroid Problems May Make Things Worse for Dialysis PatientsWhite Collar Workers at Higher Odds of Death From ALS, Parkinson'sExperimental Vaccines Might Shield Fetus From ZikaStudy Spots Cause of Global Outbreak of Infections Tied to Heart SurgeriesEducation Can Boost Knowledge, Cut Anxiety in GlaucomaReview: Little Evidence on Vitamin D-Allergy AssociationClimate Change Delivers 'Double Whammy' to 4 in 10 AmericansHealth Tip: Battling Muscle Cramps?Too Few Children Get EpiPen When Needed: StudyCPAP Mask Not a Prescription for Heart TroublesNew Criteria Urged for Infection Diagnosis Among Seniors in EREarly Parkinson's May Prompt Vision ProblemsParkinson's Patients Deemed at Higher Risk of MelanomaViagra Might Make for a Safer, More Effective StentDaily Jolt of Java May Bring Longer LifeFDA Approves Endari for the Treatment of Sickle Cell DiseaseIncreasing BMI Causally Linked to Asthma, Not Hay FeverShield Yourself From 'Swimmer's Ear'Keep Legionnaire's Disease From Spoiling Your VacationNew Opioid Use in Older Adults With COPD May Up Cardiac EventsParkinson's Disease and Melanoma May Occur Together, Study FindsRecurring Intestinal Infections on the Rise in U.S.: StudyFDA Approves New Drug for Sickle Cell DiseaseHealth Tip: Do I Need a Zika Test?Shortage of Bee, Wasp Venom Stings Those With AllergiesAre Doctors Discarding Donor Kidneys That Could Save Lives?Herpes Zoster May Increase Risk of Myocardial Infarction, StrokeHyperbaric Oxygen Therapy Increasingly Being UsedOpioids a Threat to Seniors With COPDHealth Tip: Are You at Risk for a Herniated Disk?
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

FDA Approves 1st New Drug for ALS in Decades

HealthDay News
by -- Robert Preidt
Updated: May 8th 2017

new article illustration

MONDAY, May 8, 2017 (HealthDay News) -- The first new drug to treat amyotrophic lateral sclerosis (ALS) in more than 20 years has been approved by the U.S. Food and Drug Administration.

Radicava (edaravone) is taken intravenously daily for 14 days, followed by 14 days without the drug. Subsequent treatment cycles consist of treatment for 10 out of 14 days, followed by 14 days without the drug.

"After learning about the use of edaravone to treat ALS in Japan, we rapidly engaged with the drug developer about filing a marketing application in the United States," Dr. Eric Bastings, deputy director of the division of neurology products in the FDA's Center for Drug Evaluation and Research, said in an agency news release.

"This is the first new treatment approved by the FDA for ALS in many years, and we are pleased that people with ALS will now have an additional option," Bastings added.

The very first ALS drug, riluzole, was approved by the FDA in 1995.

ALS, also known as Lou Gehrig's disease, is a progressive, always fatal neurological disease that destroys the nerve cells that control voluntary muscles, including those used for chewing, walking, breathing and talking. Most patients die from respiratory failure within three to five years after symptoms begin.

About 12,000 to 15,000 Americans have ALS, according to the U.S. Centers for Disease Control and Prevention.

The FDA's approval of Radicava was based on a six-month clinical trial in Japan that included 137 patients who received either the drug or an inactive placebo, the agency said Friday. After 24 weeks, patients taking the drug had less decline in physical functioning than those taking the placebo.

The most common side effects among patients taking the drug were bruising and walking problems, the findings showed.

"Radicava is also associated with serious risks that require immediate medical care, such as hives, swelling or shortness of breath, and [life-threatening] allergic reactions to sodium bisulfite, an ingredient in the drug," the agency said in the news release.

One ALS expert said the approval gives patients a desperately needed option.

"The effect is modest but significant," Dr. Neil Shneider, director of the Eleanor and Lou Gehrig ALS Center at Columbia University Medical Center in New York City, told The New York Times. "I'm very happy, frankly, that there is a second drug approved for ALS."

But Shneider stopped short of saying he would actually recommend it to his ALS patients, because the intravenous drug is difficult and time-consuming to administer.

"If it were a pill and easily administered, I'd be less reluctant to use it," he told the newspaper.

Shneider added that the drug will not make patients feel better or stronger; it can only slow the decline of the devastating disease.

More information

The U.S. National Institute of Neurological Disorders and Stroke has more on ALS.